$Biomea Fusion (BMEA.US)$ Biomea Fusion (NASDAQ: BMEA) announced its strategic transformation into a diabetes and obesity medicines company, focusing on icovamenib development for metabolic disorders. The company will conclude its oncology studies and explore partnerships for these assets.
Key clinical trial results for icovamenib showed:
1.5% mean reduction in HbA1c in severe insulin deficient patients vs placebo
1.0% HbA1c reduction in patients on GLP-1-based therapies
100% response ...

$Biomea Fusion (BMEA.US)$
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Monday, 13th January at 9:00 am
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones 
of the metabolic franchise
Biomea preparing icovamenib for late-stage clinical development
2025 corporate update to be presented at the 43rd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company...

$Biomea Fusion (BMEA.US)$ Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital

$Biomea Fusion (BMEA.US)$ New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared to semaglutide alone
Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose
Ex vivo human islet experiments pr...

$Biomea Fusion (BMEA.US)$ REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced today that Thomas Butler, Chief Executive Officer and Chairman of the Board, will present at the 43rd Annual J.P. Morgan Healthcare Confer...

$Biomea Fusion (BMEA.US)$ Reuters· 3 mins ago
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study Thanks @Jaguar8  For spotting since for some reason they say no more posts???

$Biomea Fusion (BMEA.US)$ Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

$Biomea Fusion (BMEA.US)$ Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
Icovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events

$Biomea Fusion (BMEA.US)$ is -without doubts- burning money at a super high speed.
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?